DYN — Dyne Therapeutics Share News
0.000.00%
Last trade - 00:00Dyne Therapeutics Q1 adjusted EPS beats expectations on lower expenses
Brief: Dyne Therapeutics Announces New Positive Cardiopulmonary Results From Deliver Trial Of Z-Rostudirsen In Duchenne Muscular Dystrophy (Dmd)
Dyne Therapeutics Q4 net loss narrows, beats analyst expectations
U.S. RESEARCH ROUNDUP-Alphabet, Micron Technology, Microsoft
Brief: Dyne Therapeutics Appoints Vikram Karnani To Board Of Directors
Brief: Dyne Therapeutics Says Co Prices Public Offering At $18.44 Per Share
Dyne Therapeutics slides after unveiling $300 million stock offering
Brief: Dyne Therapeutics Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart
Buzz Us Stocks On The Move: Tesla, Warner Bros Discovery, Netflix
Dyne Therapeutics rises after positive data for its muscle wasting drug
U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix
Brief: Dyne Therapeutics Announces Positive Topline Results From Phase 1/2 Deliver Trial
Dyne Therapeutics rises after positive data for its muscle wasting drug
U.S. RESEARCH ROUNDUP-Disney, Enanta Pharmaceuticals, Phillips 66
Dyne Therapeutics Q3 net loss beats expectations
U.S. STOCKS ON THE MOVE-PepGen, Turbo Energy, Qualcomm
PepGen, Dyne rise after Novartis' $12 bln deal to buy rival Avidity
Brief: Dyne Therapeutics Receives Orphan Drug Designation In Japan For Dyne-251 In Duchenne Muscular Dystrophy